Rigor Reviewed

Rigor-Reviewed Manuscript

Anti-sporozoite monoclonal antibody for malaria prevention: secondary efficacy outcome of a phase 2 randomized trial.

Name: Αlpha¹ Rigor Record — Anti-sporozoite monoclonal antibody for malaria prevention: secondary efficacy outcome of a phase 2 randomized trial.
Item: Anti-sporozoite monoclonal antibody for malaria prevention: secondary efficacy outcome of a phase 2 randomized trial.
Rating: 96
Author: Αlpha¹

Skinner J, Kayentao K, Ongoiba A, Healy SA, Hu Z, Preston AC, Niangaly A, Schwabl P, Cisse H, Doumbo S, Doumtabe D, Traore A, Li S, Peterson ME, Seilie AM, Chavtur C, Staubus W, Chang M, Kelley K, Traore H, Djiguiba A, Keita M, Ouattara A, Doucoure M, Keita M, Diarra D, Sylla M, Diakite D, Konate M, Traore S, Zéguimé A, Dolo A, Neafsey DE, Murphy SC, Traore B, Seder RA, Crompton PD

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3★ (Adequate), 0 critical, 3 high issues for “Anti-sporozoite monoclonal antibody for malaria prevention: secondary efficacy outcome of a phase 2 randomized trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ReportingData & code availability partially met−0.25★
CitationsUnresolved reference−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced5 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Broken references and links1

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and well-reported phase 2 randomized controlled trial with a strong scientific premise, rigorous design, and transparent reporting. The main weakness is the vague data availability statement, which lacks a concrete access mechanism, and minor reporting gaps such as not explicitly naming the CONSORT guideline and not reporting exact p-values.

Both reviewers classified the study as interventional, and this synthesis adopts that classification. The evaluation covered the full text, including methods, results, and supplementary information. Non-applicable sub-criteria (e.g., animal housing, cell line authentication) were excluded. The statistics verification recomputed only 4 tests (all consistent); the remaining statistics were not machine-verified and should not be assumed correct.

10 major claims checked against the paper's own evidence: 2 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Recomputed 4 tests: 4 consistent, 0 inconsistent; 4 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites prior research on malaria epidemiology, the limitations of current vaccines (RTS,S/AS01, R21/Matrix-M) and the need for tools that block sporozoite infection. It acknowledges the poor sensitivity of thick blood smear (TBS) as a limitation of prior trials and explains how the current study addresses this by using a more sensitive qRT-PCR assay. The rationale linking the premise to the study objectives is logical and well-supported.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior work on malaria burden, sporozoite biology, and the limitations of TBS-based efficacy assessment, and clearly justifies the need for a more sensitive endpoint.

Evidence

paraphrase[Introduction, paragraph 2]

“In phase 3 trials of RTS,S/AS01 and R21/Matrix-M, the primary efficacy endpoint was symptomatic blood-stage infection, as detected by microscopic examination of thick blood smears (TBS).”

paraphrase[Introduction, paragraph 3]

“Although TBS examination is historically the standard diagnostic assay to assess efficacy in trials of malaria vaccines and drugs in endemic areas, TBS has poor analytical sensitivity, with a limit of detection (LoD) of ~40,000 parasites per milliliter of blood.”

paraphrase[Introduction, paragraph 2]

“Because blood-stage infections can be asymptomatic, the efficacy of RTS,S/AS01 and R21/Matrix-M in preventing infection in these trials is uncertain.”

PASSReviewer 2· 95% conf

The paper clearly establishes the scientific premise by citing prior work on malaria burden, the need for new interventions, and the rationale for targeting sporozoites with CIS43LS.

Evidence

paraphrase[Introduction, paragraphs 1-3]

“The mosquito-transmitted parasite Plasmodium falciparum causes more than 200 million cases of malaria each year, resulting in approximately 600,000 deaths, mostly among children in Africa.”

paraphrase[Introduction, paragraph 4]

“Here, we present the results of a prespecified analysis of this trial in which the secondary efficacy endpoint was P. falciparum infection detected by a highly sensitive Plasmodium 18S rRNA quantitative reverse transcription–PCR (18S qRT–PCR) assay that detects asexual blood-stage parasites as well as gametocytes with a LoD of ~20 parasites per milliliter of blood.”

Randomization method (block randomization with varying block size) and unit (individual participant) are stated. Blinding is described for participants, trial team, and laboratory personnel. The modified intention-to-treat population is defined. Inclusion/exclusion criteria are referenced to the protocol. The analysis population and missing-data approach (mITT) are defined, satisfying outlier_handling. Controls (placebo arm) are appropriate. Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisINADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous: randomized, double-blind, placebo-controlled, with block randomization, blinding of participants and assessors, and a prespecified secondary endpoint analysis.

Evidence

direct quote[Methods, Clinical trial design and oversight]

“Block randomization was used with block size varying from six to nine.”